Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Niamh Coleman, Philip Thomas Murphy, Patrick Thornton & John Quinn. (2013) Pure red cell aplasia complicating chronic lymphocytic leukemia: rapid response to high-dose methylprednisolone and rituximab. Leukemia & Lymphoma 54:10, pages 2333-2335.
Read now
Read now
Lukáš Smolej. (2012) The role of high-dose corticosteroids in the treatment of chronic lymphocytic leukemia. Expert Opinion on Investigational Drugs 21:7, pages 1009-1017.
Read now
Read now
Regina Pileckyte, Mindaugas Jurgutis, Vilma Valceckiene, Mindaugas Stoskus, Egle Gineikiene, Jurgita Sejoniene, Andrius Degulys, Tadas Zvirblis & Laimonas Griskevicius. (2011) Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia. Leukemia & Lymphoma 52:6, pages 1055-1065.
Read now
Read now
Alessandra Tedeschi, Eleonora Vismara, Francesca Ricci, Enrica Morra & Marco Montillo. (2010) The spectrum of use of rituximab in chronic lymphocytic leukemia. OncoTargets and Therapy 3, pages 227-246.
Read now
Read now
Farrukh T. Awan, Amy J. Johnson, Rosa Lapalombella, Weihong Hu, Margaret Lucas, Beth Fischer & John C. Byrd. (2010) Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia. Leukemia & Lymphoma 51:1, pages 27-38.
Read now
Read now
Kevin Boyd & Claire E Dearden. (2008) Alemtuzumab in the treatment of chronic lymphocytic lymphoma. Expert Review of Anticancer Therapy 8:4, pages 525-533.
Read now
Read now
Andrew R. Pettitt. (2008) Glucocorticoid-based combination therapy for chronic lymphotic leukemia: new tricks for an old dog. Leukemia & Lymphoma 49:10, pages 1843-1845.
Read now
Read now
J. P. Quinn, S. Mohamedbhai, K. Chipperfield, M. Treacy, S. D'Sa & A. C. Nathwani. (2008) Efficacy of rituximab in combination with steroids in refractory chronic lymphocytic leukemia. Leukemia & Lymphoma 49:10, pages 1995-1998.
Read now
Read now
Deborah A. Bowen, Timothy G. Call, Greg D. Jenkins, Clive S. Zent, Susan M. Schwager, Daniel L. Van Dyke, Diane F. Jelinek, Neil E. Kay & Tait D. Shanafelt. (2007) Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leukemia & Lymphoma 48:12, pages 2412-2417.
Read now
Read now
. (2007) Abstracts from the XII International Workshop on CLL. Leukemia & Lymphoma 48:sup1, pages 1-186.
Read now
Read now
Arthur E Frankel, Donald R Fleming, Bayard L Powell & Ronald Gartenhaus. (2003) DAB389IL2 (ONTAK®) fusion protein therapy of chronic lymphocytic leukaemia. Expert Opinion on Biological Therapy 3:1, pages 179-186.
Read now
Read now
Alexander S.D. Spiers. (2001) Management of the Chronic Leukemias: Special Considerations in the Elderly Patient. Part I. Chronic Lymphocytic Leukemias. Hematology 6:5, pages 291-314.
Read now
Read now
Articles from other publishers (26)
Ana Vagos Mata, Eduardo Espada, Daniela Alves, Blanca Polo, Maria João Costa, Conceição Lopes, João F. Lacerda & João Raposo. (2021) Chronic lymphocytic leukaemia/small lymphocytic lymphoma treatment with rituximab and high‐dose methylprednisolone, revisited. Cancer Medicine 10:24, pages 8768-8776.
Crossref
Crossref
Martin Šimkovič, Pavel Vodárek, Monika Motyčková, Dominika Écsiová, Petra Rozsívalová, Heidi Móciková, Pavla Štěpánková, Alice Sýkorová, Kateřina Hrochová, Filip Vrbacký, David Belada, Pavel Žák & Lukáš Smolej. (2020) Rituximab, Cyclophosphamide and Dexamethasone (RCD) Chemoimmunotherapy for Relapsed Chronic Lymphocytic Leukaemia. European Journal of Clinical Investigation 51:4.
Crossref
Crossref
Farrukh T. Awan & John C. Byrd. 2020. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
1850
1871.e5
.
Daniel Heudobler, Michael Rechenmacher, Florian Lüke, Martin Vogelhuber, Sebastian Klobuch, Simone Thomas, Tobias Pukrop, Christina Hackl, Wolfgang Herr, Lina Ghibelli, Christopher Gerner & Albrecht Reichle. (2018) Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis. Frontiers in Pharmacology 9.
Crossref
Crossref
Michael Doubek, Yvona Brychtova, Anna Panovska, Ludmila Sebejova, Olga Stehlikova, Jana Chovancova, Jitka Malcikova, Jana Smardova, Karla Plevova, Pavlina Volfova, Martin Trbusek, Marek Mraz, Denisa Bakesova, Jakub Trizuljak, Marketa Hadrabova, Petra Obrtlikova, Josef Karban, Lukas Smolej, Alexandra Oltova, Eva Jelinkova, Sarka Pospisilova & Jiri Mayer. (2015) Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study. American Journal of Hematology 90:5, pages 417-421.
Crossref
Crossref
Panfeng Yu, Hongwei Ma, Yong Shang, Ji Wu & Shun Shen. (2014) Polyethylene glycol modified magnetic carbon nanotubes as nanosorbents for the determination of methylprednisolone in rat plasma by high performance liquid chromatography. Journal of Chromatography A 1348, pages 27-33.
Crossref
Crossref
John C. Byrd & Joseph M. Flynn. 2014. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
1958
1978.e7
.
Ohad Benjamini, Alessandra Ferrajoli & Michael J Keating. (2013) Approach to frontline therapy in elderly chronic lymphocytic leukemia patients. Aging Health 9:3, pages 331-347.
Crossref
Crossref
Carlo Visco, Silvia Finotto, Fabrizio Pomponi, Roberto Sartori, Francesco Laveder, Livio Trentin, Rossella Paolini, Eros Di Bona, Marco Ruggeri & Francesco Rodeghiero. (2013) The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high‐risk patients with chronic lymphocytic leukemia. American Journal of Hematology 88:4, pages 289-293.
Crossref
Crossref
Kang Lu & Xin Wang. (2012) Therapeutic advancement of chronic lymphocytic leukemia. Journal of Hematology & Oncology 5:1.
Crossref
Crossref
Barbara Vannata, Idanna Innocenti, Francesco Autore, Federica Sorà, Patrizia Chiusolo, Giuseppe Leone, Simona Sica & Luca Laurenti. (2012) High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia. American Journal of Hematology 87:12, pages E133-E133.
Crossref
Crossref
Maria Joao Baptista, Ana Muntañola, Eva Calpe, Pau Abrisqueta, Olga Salamero, Eva Fernández, Carles Codony, Eva Giné, Susana G. Kalko, Marta Crespo & Francesc Bosch. (2012) Differential Gene Expression Profile Associated to Apoptosis Induced by Dexamethasone in CLL Cells According to IGHV/ZAP-70 Status. Clinical Cancer Research 18:21, pages 5924-5933.
Crossref
Crossref
Lukáš Smolej, Michael Doubek, Anna Panovská, Martin Šimkovič, Yvona Brychtová, David Belada, Monika Motyčková & Jiří Mayer. (2012) Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia. Leukemia Research 36:10, pages 1278-1282.
Crossref
Crossref
Marays VelizJavier Pinilla-Ibarz. (2012) Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia. Cancer Control 19:1, pages 37-53.
Crossref
Crossref
Saman Hewamana & Claire Dearden. (2011) Treatment options for high-risk chronic lymphocytic leukaemia. Therapeutic Advances in Hematology 2:3, pages 147-159.
Crossref
Crossref
Karen W. L. Yee & Susan M. O'Brien. 2011. Management of Hematologic Malignancies. Management of Hematologic Malignancies
81
102
.
Panfeng Yu, Qi Wang, Xifeng Zhang, Xuesong Zhang, Shun Shen & Yan Wang. (2010) Development of superparamagnetic high-magnetization C18-functionalized magnetic silica nanoparticles as sorbents for enrichment and determination of methylprednisolone in rat plasma by high performance liquid chromatography. Analytica Chimica Acta 678:1, pages 50-55.
Crossref
Crossref
Samantha M. Jaglowski & John C. Byrd. (2010) Rituximab in Chronic Lymphocytic Leukemia. Seminars in Hematology 47:2, pages 156-169.
Crossref
Crossref
Emeline De Viron, Laurent Knoops, Thierry Connerotte, Caroline Smal, Lucienne Michaux, Pascale Saussoy, Pascal Vannuffel, Eline Beert, Marie‐Christiane Vekemans, Cédric Hermans, Françoise Bontemps & Eric Van Den Neste. (2009) Impaired up‐regulation of polo‐like kinase 2 in B‐cell chronic lymphocytic leukaemia lymphocytes resistant to fludarabine and 2‐chlorodeoxyadenosine: a potential marker of defective damage response. British Journal of Haematology 147:5, pages 641-652.
Crossref
Crossref
S Faderl, A Ferrajoli, O Frankfurt & A Pettitt. (2008) Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy. Leukemia 23:3, pages 457-466.
Crossref
Crossref
J E Castro, J D Sandoval-Sus, J Bole, L Rassenti & T J Kipps. (2008) Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 22:11, pages 2048-2053.
Crossref
Crossref
Dominic Thibeault, Jenny Roy, Patrick DeRoy & Donald Poirier. (2008) Chemical synthesis of 2?-amino-5?-androstane-3?,17?-diol N-derivatives and their antiproliferative effect on HL-60 human leukemia cells. Bioorganic & Medicinal Chemistry 16:9, pages 5062-5077.
Crossref
Crossref
Rajendra N. Goyal, Neeta Bachheti, Anuradha Tyagi & Ashish K. Pandey. (2007) Differential pulse voltammetric determination of methylprednisolone in pharmaceuticals and human biological fluids. Analytica Chimica Acta 605:1, pages 34-40.
Crossref
Crossref
John A. Meyers, Josephine Taverna, Jorge Chaves, Anthony Makkinje & Adam Lerner. (2007) Phosphodiesterase 4 Inhibitors Augment Levels of Glucocorticoid Receptor in B Cell Chronic Lymphocytic Leukemia but Not in Normal Circulating Hematopoietic Cells. Clinical Cancer Research 13:16, pages 4920-4927.
Crossref
Crossref
Gerassimos A. Pangalis, Theodoros P. Vassilakopoulos, Maria N. Dimopoulou, Marina P. Siakantaris, Flora N. Kontopidou & Maria K. Angelopoulou. (2002) B‐chronic lymphocytic leukemia: practical aspects. Hematological Oncology 20:3, pages 103-146.
Crossref
Crossref
Thomas J. Kipps. (2000) Chronic lymphocytic leukemia. Current Opinion in Hematology 7:4, pages 223-234.
Crossref
Crossref